# The impact of monoallelic inactivation mutations in the ENPP1 gene on pediatric skeletal development: a case report and literature review

**Authors:** Siyi Lu, Ning Sun, Yuan Li, Zongyi Wu, Jingdong Zhang

PMC · DOI: 10.3389/fendo.2025.1430681 · 2025-04-09

## TL;DR

A 17-year-old boy with a rare bone disorder caused by a mutation in the ENPP1 gene highlights its role in pediatric skeletal development.

## Contribution

This case report identifies the clinical impact of monoallelic ENPP1 inactivation mutations in children.

## Key findings

- A monoallelic inactivation mutation in the ENPP1 gene was found to affect calcium and phosphorus metabolism in a pediatric patient.
- The mutation led to skeletal abnormalities including femoral metaphysis and acetabulum defects.
- The case provides insights for diagnosing and managing bone diseases related to ENPP1 mutations in children.

## Abstract

Recently, in our clinical work, we discovered a case of abnormal bone metabolism in children resulting from an inactivated mutation of the ENPP1 gene. Through this discovery, we highlighted the impact of the ENPP1 gene on the skeletal growth and development of children, and provided new ideas for the clinical diagnosis of bone diseases in children.

A 17-year-old boy presented with abnormal gait and hip pain. The anteroposterior (AP) pelvis X-ray revealed bilateral abnormalities in the femoral metaphysis, acetabulum, and ilium bones, as well as slippage of the left femoral head epiphysis. After genetic testing was carried out, it was found that the patient had a monoallelic inactivation mutations in the ENPP1 gene, which is the pathogenic gene of Autosomal-Recessive Hypophosphatemic Rickets 2 (ARHR2). Genetic testing identified that the patient had an inactivating mutation in the ENPP1 gene, which is associated with Autosomal-Recessive Hypophosphatemic Rickets 2 (ARHR2). Since symptoms were present at the time of diagnosis, the current treatment plan includes symptomatic treatments, such as calcium supplementation and femoral epiphyseal fixation.

We discovered that the inactivating mutation of the ENPP1 gene has an influence on bone metabolism, particularly calcium and phosphorus metabolism, which can lead to severe adverse effects on the growth and development of pediatric patients. Through this case and a review of the literature, we aim to enable clinical physicians to establish a holistic perspective during pediatric consultations.

## Linked entities

- **Genes:** ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) [NCBI Gene 5167]

## Full-text entities

- **Genes:** ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) [NCBI Gene 5167] {aka ARHR2, COLED, M6S1, NPP1, NPPS, PC-1}
- **Diseases:** bone diseases (MESH:D001847), abnormal gait (MESH:D020233), slippage of the left femoral head epiphysis (MESH:D000070603), hip pain (MESH:D010146), ARHR2 (MESH:C567647), abnormal bone metabolism (MESH:D001851)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12015756/full.md

---
Source: https://tomesphere.com/paper/PMC12015756